Maricann Group, Inc. Stock (OTC: MRRCF) (CSE: MARI) - Investor Dashboard

Summary

Financials (06/30/17)

Capital Structure (8/28/17)

Company Brief

Maricann Group Inc., was founded in 2013 and is based in a well-established agricultural region in southwestern Ontario, Canada. In March of 2014 Maricann earned a Health Canada license to cultivate plants and in December earned a license from Health Canada to sell dried flower.

The company sold $1.97mm dried cannabis in 2015, and purchased 97.5 contiguous acres while earning a license to sell cannabis extracts in September. Maricann, which has partnered with Evolab, its Colorado-based extraction technology partner, to access its leading technology and processes, made its first sale of extracted cannabis in October.

The Maricann Langton Facility produced sales of $4.2mm in 2016 and is expected to almost triple production in 2017 following expansion and the introduction of new products. Maricann grows all-natural plants in its energy-efficient greenhouse, while maintaining secure and consistent supply, as it has focused on 8 profitable and proven strains and is aiming for production costs of $1.34 per gram.

Maricann is currently expanding domestic and international capacity and distribution channels. In Germany, Maricann has commenced  a retrofit of a 500,000 sq. ft. cultivation facility which is currently underway, and is preparing to cultivate all-natural plants in a portion of the facility in Dresden. The company has raised $35mm in capital since November.

Expanding in Mature Markets

Maricann’s GMP-compliant clean-room cultivation facility in Dresden, Germany leaves it very well positioned for growth in a large market.

German Parliamentarians voted unanimously in January 2017 in favor of the new “Cannabis as Medicine” law, which will create a large market with insurance coverage and pharmacy distribution and will allow Maricann to expand throughout the European Union.

Highlights

• Licensed by Health Canada since 2014
• Focus on both Medical and Lifestyle cannabis
• Management team experienced in cultivation, pharmaceuticals, distribution and healthcare
• Selling dried flower, oils, resin and clones
• $35mm capital raised since November 2016
• Forecasting strong production and sales growth following facilities expansion

Growth Strategy

• Expanding Langton, Ontario greenhouse in two phases
• Dresden, Germany GMP-compliant cultivation facility to allow EU expansion if company is successful in obtaining a license
• Virtual pharmacies in physical locations and seminars and education offered by Synergy Health Clinics
• Considering acquisitions

Differentiators

• Focus on energy efficiency using glass greenhouse
• Intending to apply for a German cultivation license
• Focus on 8 proven and profitable strains
• Joint venture with Evolab, a leading Colorado extraction technology partner